| 42.57 Delayed Data As of Aug 22 |  -0.63 / -1.46%Today’s Change | 40.00 Today|||52-Week Range 45.62 | -1.94% Year-to-Date |
| Pfizer's Xtandi Label Expansion Filing Gets Priority Review Aug 22 / Zacks.com - Paid Partner Content | Should Value Investors Consider Sanofi (SNY) Stock Now? Aug 14 / Zacks.com - Paid Partner Content |
| Is Sanofi (SNY) a Great Value Stock Right Now? Aug 22 / Zacks.com - Paid Partner Content | J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients Aug 12 / Zacks.com - Paid Partner Content |
| Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Aug 20 / Zacks.com - Paid Partner Content | AnaptysBio Prepares for a Potential Gear Shift Aug 10 / MotleyFool.com - Paid Partner Content |
| Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe Aug 15 / Zacks.com - Paid Partner Content |
| Previous close | 43.20 |
| Today’s open | 42.85 |
| Day’s range | 42.55 - 42.96 |
| Volume | 979,319 |
| Average volume (3 months) | 1,442,026 |
| Market cap | $104.7B |
| Earnings growth (last year) | +19.94% |
| Earnings growth (this year) | +4.43% |
| Earnings growth (next 5 years) | +4.50% |
| Revenue growth (last year) | +2.83% |
| P/E ratio | 26.9 |
| Price/Sales | 2.68 |
| Price/Book | 1.55 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | +0.15 | +0.13% |
| GSKGlaxoSmithKline | +0.29 | +0.71% |
| ABBVAbbVie | -0.02 | -0.03% |
| AZNAstraZeneca | -0.01 | -0.02% |
| Next reporting date | October 31, 2019 |
| EPS forecast (this quarter) | $1.00 |
| Annual revenue (last year) | $40.7B |
| Annual profit (last year) | $5.1B |
| Net profit margin | 12.53% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
